


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

UPDATE ON RESUMPTION

References are made to the announcement of China Wah Yan Healthcare Limited (the “Company”) dated 1 February 2019. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the said announcement.

The Company wishes to announce that BDO Limited has been appointed to assist the Independent Committee relating to the Investigation. The Company will keep its shareholders posted of the Investigation as and when appropriate.

Trading in the shares of the Company will continue to be suspended since the Resumption Conditions have not been fulfilled. The Company will update its shareholders and potential investors on any material development relating to the resumption of trading in its shares as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the board of directors of
China Wah Yan Healthcare Limited
Chan Ka Chung
Chairman

Hong Kong, 11 March 2019

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Mr Tsang Hung Kei.